Effects of cyclin-dependent kinase inhibitors (CDK4/6) on pre-clinical models of bone metastases from breast cancer

Project objectives

• analyze the direct inhibitory effect of CDK4/6 on the differentiation and activity of primary human osteoclasts and osteoblasts
• investigate a possible indirect antitumor effect, mediated by osteoblasts, of CDK4/6 inhibitors
• evaluate the direct antitumor effect of CDK4/6 inhibitors in models vitro of bone metastases of breast cancer
• retrospectively analyze skeletal outcome data (time to onset of the first skeletal event, time to bone progression) in patients with breast cancer treated with hormonal therapy alone or in combination with CDK4/6 inhibitors
• prospectively evaluate markers of bone turnover in patients with breast cancer undergoing treatment with CDK4/6 inhibitors

Start and end date

Project Manager

Coordinating institution of the project

Other Institutions involved

• Center for Osteoncology and Rare Tumors, IRCCS Romagna Scientific Institute for the Study and Treatment of Tumors (IRST)
• Department of Medical-Surgical Sciences and Biotechnology, La Sapienza University
• European Institute of Oncology, IRCCS
• National Institute for the Study and Treatment of Tumors, Pascale IRCCS Foundation

Primary funding source